12.02.2025 • NewsFujifilminvestmentsemiconductors

Fujifilm Ramps up Capacity for Semiconductor Materials in Belgium

Fujifilm plans to invest approximately €25 million to install new production facilities for chemical mechanical planarization (CMP) slurries, which are used in advanced semiconductors, as well as enhance existing facilities for photolithography-related materials at its site in Antwerp, Belgium.

This expansion aims to meet the growing demand for automotive and industrial semiconductors in Europe, the company said.

The new facility for CMP slurries will expand Fujifilm’s global network to a total of six, with further sites in the US, Taiwan, South Korea and Japan.

In addition, Fujifilm will enhance the production facilities for developer used in the photolithography process at the Belgium site. This will help the company meet the increasing demand for automotive and industrial semiconductors in Europe and respond to the high-quality requirements of its customers, Fujifilm said.

The new CMP slurry production facilities and the enhanced developer production facilities are both scheduled to start operation in the spring of 2026.

© Nicolas Loran/iStockphoto
© Nicolas Loran/iStockphoto

Company

Logo:

Fujifilm


Tokyo
Japan

Company contact







Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

most read

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.